Kidney transplant study compares immune effects of two common drugs

NCT ID NCT02894606

Completed Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 49 kidney transplant patients to see how two different induction therapies—thymoglobulin and basiliximab—affect B cells, a type of immune cell. Researchers compared the B cell profiles between the two groups and with data from patients who had chronic antibody-mediated rejection. The goal was to better understand how these drugs influence the immune system after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Thymoglobulin and basiliximab (induction therapies given before kidney transplant to prevent rejection)
What this could lead to: If successful, this could help doctors choose the best induction therapy for kidney transplant patients and reduce the risk of chronic rejection.
What could go wrong: This is a small, observational study that does not test a new treatment. It only looks at immune cell changes, so it may not lead to direct improvements in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL TRANSPLANT

Contacts and locations

Locations

CHU Brest

Brest, 29200, France
Tours University Hospital

Tours, 37000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.